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OBJECTIVES: AECOPD is a leading cause of hospitalization.
A valid and easy-to-use risk stratiﬁcation tool applicable not
only for clinical but also economic outcomes would facilitate
population-based outcome studies. We sought to validate an
AECOPD clinical risk stratiﬁcation tool previously reported and
determine its utility for economic outcomes. METHODS: We
analyzed 57,791 AECOPD admissions in 2004–2005 across 191
USA hospitals. The AECOPD risk stratiﬁcation tool identiﬁed
three factors with the highest discrimination of mortality risk:
BUN > 25 mg/dl, Altered mental status, and Pulse > 109 per
minute (BAP). Based on the number of risk factors present on
admission, the BAP classiﬁed patients into four risk categories,
ranging from Low (0 risk factors) to High (3 factors). We exam-
ined mortality, length of stay (LOS), and cost outcomes using the
BAP classiﬁcation algorithm. The cost outcome was calculated
using the Centers for Medicare and Medicaid Services (CMS)
cost/charge ratio for each hospital for a given calendar year.
RESULTS: Overall, median age was 72 (IQR: 63–79) and 55%
were women. Crude mortality was 2.4%. The prevalence for
each of the BAP risk categories was 51.6% (low), 39.7% (Inter-
mediate I), 7.9% (Intermediate II), and 0.8% (High). The corre-
sponding mortality was 1.0%, 2.7%, 8.2%, 17.6%; the mean
LOS was 4.7, 5.4, 6.6, 6.8 days; the mean cost were $5,700,
$6,900, $9,400, $11,400 respectively. The trend-analyses
revealed a graded association between number of BAP risk
factors and worsening outcomes. For every addition of BAP risk
factors, there was an exponential increase in mortality risk (OR:
2.89, CI: 2.70–3.09), 0.81 day increase of LOS (CI: 0.76–0.87),
and $1600 increase of cost (CI: $1500–$1700). P-values for all
trends were <0.0001. CONCLUSIONS: The BAP classiﬁcation
tool accurately differentiates mortality risk. It may also be used
to identify high risk cohorts for prolonged LOS and excess cost
among hospitalized AECOPD patients.
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OBJECTIVE: To determine factors predictive to survival for
patients transferred to respiratory care ward after prolonged
mechanical ventilation. METHODS: We reviewed medical
records in a hospital in southern Taiwan between January 1,
2003 and December 31, 2006 to collect clinical data while trans-
ferred to respiratory care ward. The National death certiﬁcation
database of Taiwan was linked to ascertain the date of death.
Kaplan-Meier estimation was performed for survival analysis;
Cox proportional hazards model was constructed based on
various patient characteristics, including age, gender, education,
co-morbidity with diabetes, stroke, chronic obstructive pulmo-
nary disease, end stage renal disease and blood platelet. A strat-
egy of backward selection was taken. RESULTS: Two hundred
and eighty-seven patients who required chronic mechanical ven-
tilation in intensive care unit were included in this study. Their
median age was 77 years, 56% were male. Survival rate of 90
days and 180 days following transfer to respiratory care ward
were 70 and 50%, respectively. After taking age, gender, and
various co-morbidity into consideration, the adjusted hazard
ratios for end stage renal disease and abnormal blood platelet
count were 1.56 (95% conﬁdence interval (CI), 1.12–2.15) and
1.40 (95%CI, 1.04–1.90), respectively. CONCLUSION: Overall
survival of patients with prolonged mechanical ventilation was
poor, especially for patients with end stage renal disease or/and
abnormal blood platelet count.
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OBJECTIVE: Each year, asthma accounts for 3 million clinic
visits, 550,000 emergency room visits, 150,000 hospitalizations,
and 150 deaths in children under ﬁfteen. Literature suggests that
asthmatic children exposed to tobacco smoke experience com-
plications of greater frequency and severity than those unex-
posed. This study proposes to test the hypotheses that asthmatic
children exposed to household tobacco smoke experience more
frequent and severe exacerbations and have greater inhaler use
than those unexposed. METHODS: NHANES’ 2003–2004 data-
base was queried to identify a cohort of 421 asthmatic children
(ages 0–17) with current diagnosis of asthma and complete
demographic, examination, and questionnaire data. The cohort
was analyzed based on exposure to household tobacco smoke.
Logistic regression was used to examine emergency room (ER)
visit, wheezing frequency, and recent inhaler use. RESULTS:
Results revealed no signiﬁcantly greater frequency or severity of
asthma outcomes in children exposed to tobacco smoke. House-
hold smoke exposure was only signiﬁcantly associated with
inhaler use. Oddly, asthmatic children living in smoking house-
holds were highly unlikely to have used an inhaler in the past
month (Odds Ratio = 0.493, p = 0.0406). Tobacco smoke expo-
sure was associated with higher odds of wheezing attacks, but
lower odds of ER visit (though neither was signiﬁcant). CON-
CLUSION: Despite results, opportunities to improve asthma
outcomes exist. In the sample, children in smoking households
were more likely to be African American, female, live below the
poverty level, and be exposed to other indoor pollutants that
trigger asthma exacerbations. Initiatives targeted to this group
may improve asthma outcomes through education on reduction/
elimination of unnecessary indoor allergens. Study limitations
include small sample size, potential recall bias due to self or
parental-report, lack of data related to family smoking and
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OBJECTIVE: Smoking, a leading cause of morbidity and mor-
tality in the US, results in approximately 440,000 deaths, eco-
nomic costs of $96.8 billion, and losses of more than 5.6 million
years of potential life each year. The aim of this study was to
compare the costs and effectiveness of the new drug varenicline
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